期刊文献+

颅底脊索瘤Brachyury、Galectin-3与临床特征相关性研究 被引量:2

The relationshipbetween Brachyury, Galectin - 3 expression in skull base chordoma and clinical characteristics
原文传递
导出
摘要 目的探讨颅底脊索瘤Brachyury和Galectin-3蛋白表达与患者临床特征的相关性。方法回顾性分析28例经手术治疗的颅底脊索瘤患者的临床资料并进行随访,采用免疫组化方法对收集的标本行Brachyury和GMectin-3蛋白检测。结果28例中经典型23例,软骨型1例,未分化型4例,Brachyury和Galectin-3蛋白免疫组化染色均为阳性。未分化型Brachyury的表达低于经典型(P=0.011),未分化型Galectin-3蛋白表达高于经典型(P=0.018)。结论Brachyury和Galectin-3蛋白表达水平与病理类型相关,恶性度高的未分化型Brachyury表达低于其他两型,GMectin-3蛋白在未分化型中表达高于经典型。Brachyury和Galectin-3蛋白表达水平可作为预测患者预后的参考因素。 Objective The goal of this study was to report on the expression of Brachyury and Galectin- 3 protein in chordoma and their correlation with the patients' clinical characteristics. Methods The author retrospectively studied data from 28 patients with skull - base chordoma who had undergone surgeries in the Department of Skullbase and Brain Stem of Beijing Tiantan Hospital between 2005 and 2012, and follow up was performed through recheck in out- patient department, telephone and letter. Paraffin - embedded chordoma specimens of these patients was made after their surgeries, the pathological type can be confirmed by hematoxylin - eosin (HE) staining, Brachyury and Galectin - 3 expression was investigated by immunohistochemistry. Spss 13.0 was used to analysis the related data. Results In these 28 specimens, 23 are typical type, 1 is chondroid type and 4 are atypical type, all specimens contain chordoma tumor cells whichexpressbrachyury and Galeetin - 3 strongly. Brachyury protein level is lower in atypical chordomas than that in typical chordomas ( P = 0. 011 ) and chondroid chordoma ( P = 0. 004 ), while the atypical ones express higher level Galectin -3 than typical chordomas (P = 0. 018 ). Conclusions All specimens expressed Brachyury and Galectin - 3 strongly, and the expression level of these two proteins have no correlation with patients' age, sex, history of treatment and size of tumor while correlate obviously with their pathologies. The atypical ehordoma is comparatively more malignant than typical ehordoma and ehondroid ehordoma. Brachyury level is lower in atypical chordomas than that in the other two types ; Gal - 3 protein level is higher in atypical chordomas than that in the typical ones. Brachyury and Gal- 3 protein level of the tumor are important factors in forecasting patients' prognosis.
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第8期765-768,共4页 Chinese Journal of Neurosurgery
基金 国家自然青年科研课题(81101910) 首都医科大学基础临床合作课题(11JL-L09)
关键词 脊索瘤 BRACHYURY GALECTIN-3 免疫组化 Chordoma Brachyury Galectin - 3 Immunohistochemistry
  • 相关文献

参考文献16

  • 1Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notoebordaldevelopment, is a novel biomarker for ehordomas. J Patho1,2006,209 : 157-165.
  • 2Mcmaster ML, Goldstein AM, Bromley CM, et al. Chordoma: inc- idence and survival patterns in the United States, 1973- 1995. Cancer Causes Control ,2001,12 : 1-11.
  • 3Feigl GC, Bundschuh O, Gharabaghi A, et al. Evaluation of a new concept for the management of skull basechordomas and chondrosareomas. J Neurosurg,2005,102 Suppl: 165-170.
  • 4Wu Z, Zhang J, Zhang L, et al. Prognostic factors for long-term outcome of patients with surgical resection of skull basechordomas-106 cases review in one institution. Neurosurg Rev, 2010,33:451-456.
  • 5吴震,张俊廷,张力伟,贾桂军,王亮.颅底脊索瘤的长期随访研究[J].中华外科杂志,2007,45(16):1118-1120. 被引量:7
  • 6Samii A, Gerganov VM, Herold C, et al. Chordomas of the skull base : surgical management and outcome. J Neurosurg,2007,107 : 319-324.
  • 7张俊廷,王亮,吴震,贾桂军,张力伟.颅底脊索瘤患者生存因素分析[J].中华医学杂志,2007,87(23):1607-1610. 被引量:7
  • 8Romeo S, Hogendoom PC. Brachyury and chordoma: the ehondr- oid-chordoid dilemma resolved? . J Patho1,2006,209:143-146.
  • 9ShenJ, Li CD, Yang HL, et al. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of braehyury and galeetin- 3. J Clin Neurosci,2011,18:96-99.
  • 10Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vschondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol,2008,21:1461-1469.

二级参考文献22

共引文献11

同被引文献26

  • 1邱吉庆,许海洋,于洪泉,刘兴吉,王海峰,李嘉辉,于金录,赵刚.颅底脊索瘤的诊断、分型与手术入路选择[J].中国微侵袭神经外科杂志,2007,12(7):296-298. 被引量:4
  • 2Kendall BE. Cranial chordomas[J]. Br J Radiol, 1977,50: 687 -698.
  • 3MemasterML, GoldsteinAM, BromleyCM, etal. Chordoma: incidence and survival patterns in the United States, 1973-1995 [ J ]. Cancer Causes Control,2001,12 : 1-11.
  • 4Higinbotham NL, Phillips RF, Farr HW, et al. Chordoma. Thirty-five-year study at Memorial Hospital [ J]. Cancer, 1967, 20 : 1841-1850.
  • 5Raz A, Memmsky L, Zvibel I, et al. Transformation-related changes in the expression of endogenous cell lectins [ J ]. Int J Cancer, 1987,39 : 353 -360.
  • 6Roff CF, Wang JL. Endogenous lectins from cultured ceils. Isolation and characterization of carbohydrate-binding proteins from 3T3 fibroblasts[ J]. J Biol Chem, 1983,258 : 10657-10663.
  • 7Ho MK, Springer TA. Mac-2, a novel 32,000 Mr mouse macrephage subpopulation-specific antigen defined by monoclonal antibodies [ J ]. J Immunol, 1982,128 : 1221-1228.
  • 8Cerra RF, Girt MA, Barondes SH. Three soluble rat beta- galactoside-binding leetins [ J ] . J Biol Chem, 1985, 260: 10474-10477.
  • 9Barondes SH, Castronovo V, Cooper DN, et al. Galeetins : a family of animal beta-galaetoside-binding leetins[ J]. Cell,1994, 76:597-598.
  • 10Raimond J, Zimonjie DB, Mignon C, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22 [ J ]. Mamm Genome, 1997,8:706-707.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部